Neuropeptide receptors as potential pharmacological targets for obesity
-
Add time:08/28/2019 Source:sciencedirect.com
Obesity is a chronic multifactorial disease, characterized by an excessive accumulation of adipose tissue. It is usually the result of excessive food intake and/or low energy expenditure. Obesity can be triggered by lifestyle, nutritional, genetic, environmental, hormonal and psychological factors. Several strategies are used to treat obesity, including dietary reeducation, with balanced food intake, increased physical exercise, in order to promote energy expenditure and to overcome the insufficiency in weight reduction by other strategies, and administration of drugs. However, these medications are associated to undesirable side effects, resulting in a high withdrawal rate. Several studies have been focused on the development of compounds that act in the hypothalamic region where the center of the regulation of hunger and satiety is located. Some of them target the activity of endogenous peptides, such as ghrelin pancreatic polypeptide, peptide YY and neuropeptide Y, as well as their receptors. This review addresses the importance of understanding the neuropeptide/peptide hormones and their receptors for the development of novel anti-obesity compounds that may aid in weight reduction as a promising alternative for the treatment of obesity.
We also recommend Trading Suppliers and Manufacturers of NEUROPEPTIDE Y (13-36) (PORCINE) (cas 113662-54-7). Pls Click Website Link as below: cas 113662-54-7 suppliers
Prev:Pharmacological characterization of the cloned neuropeptide Y y6 receptor
Next:SERS characterization of neuropeptide Y and its C-terminal fragments deposited onto colloidal gold nanoparticle surface) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Molecular cloning, tissue distribution, and effect of fasting and refeeding on the expression of neuropeptide Y in Channa argus08/30/2019
- SERS characterization of neuropeptide Y and its C-terminal fragments deposited onto colloidal gold nanoparticle surface08/29/2019
- Pharmacological characterization of the cloned neuropeptide Y y6 receptor08/27/2019
- ReviewThe role of neuropeptide Y in the pathophysiology of atherosclerotic cardiovascular disease☆08/26/2019
- Centrally injected neuropeptide Y (13–36) produces vasopressor effects and antagonizes the vasodepressor action of neuropeptide Y (1–36) in the awake male rat08/25/2019
- Subchapter 25B - Neuropeptide Y08/24/2019
- Research ArticleNeuropeptide Y is Up-regulated and Induces Antinociception in Cancer-induced Bone Pain☆08/23/2019
- NeuroPeptide Y [13-36]08/22/2019
- Galanin(1-13)-Trp-32-Neuropeptide Y(25-36)Amide08/21/2019
-
Health and Chemical more >


